{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'hepatitis C was associated with a decreased risk of hepatocellular carcinoma (HR=0.25; 95% CI: 0.09-', '0.65; p=0.004) [87]. In the study of Barron et al. women treated with propranolol (n=70) or atenolol', '(n=525) in the year prior to breast cancer diagnosis were matched with women not receiving B-', 'blocker treatment (n=4738). Patients in the propranolol group had lower risk of having T4 (odds ratio', '[OR]=0.24, 95% CI: 0.07-0.85) or N2/N3/M1 (OR=0.20; 95% CI: 0.04-0.88) tumor compared with', 'matched non-users. The cumulative probability of breast cancer-specific mortality was significantly', 'lower for propranolol users compared with matched nonusers (HR=0.19; 95% CI: 0.06-0.60). There', 'was no difference in T4 or N2/N3/M1 tumor incidence or breast cancer-specific mortality between', 'atenolol users and matched non-users [88].', 'Propranolol was also assessed in small interventional studies. In a series of seven cases of advanced', 'angiosarcoma, propranolol (40 mg twice daily) was combined with weekly vinblastine (intravenous', '[IV] 6 mg/m\u00b2 to a maximum of 10 mg) and methotrexate (35 mg/m\u00b2 to a maximum of 50 mg) for up', 'to 12 months followed by maintenance of propranolol (40 mg twice daily), oral etoposide (50', 'mg/day) and oral cyclophosphamide (50 mg/day) for 20 consecutive days in cycles of 30 days. The', 'treatment was well tolerated and resulted in ORR of 100%. Median PFS and os were 11 months', '(range 5-24) and 16 months (range 10-30), respectively [89]. A combination of propranolol (20 mg', 'twice daily, then titrated to maintain heart rate around 80 per minute) plus etodolac (400 mg twice', 'daily) with metronomic temozolomide was compared to temozolomide monotherapy in 32 patients', 'with recurrent glioblastoma. Patients treated with combination therapy had greater median time to', 'progression (8.8 months versus 5.2 months), 6-months survival rate (63% versus 40%) and 1-year', 'survival rate (22% versus 12%) than those treated with temozolomide monotherapy, respectively', '[90]. The same combination of propranolol and etodolac was tested with concomitant nab-paclitaxel', 'plus gemcitabine in advanced pancreatic cancer. Patients randomized to four-drug therapy had', 'greater PFS (11.8 months versus 7.2 months) and os (15.9 months versus 10.5 months) than those', 'receiving standard two-drug, respectively. Additionally, patients receiving propranolol plus etodolac', 'experienced reduced pain and neuropathy and increased weight gain [91]. As a \u00df-blocker,', 'propranolol may also reduce the level of emotional distress, measured in terms of the number and', 'rate of intrusive thoughts, associated with a cancer diagnosis [92].', '1.2.4 Safety Results', 'Propranolol is generally a well tolerated drug. Its adverse effects are listed in Section 7.2.2. The', 'initiation of propranolol may lead to initial adverse effects which may resolve during dose titration to', 'a', 'maintenance dose. Sudden termination of treatment is not advised. The dose should be tapered', 'rather than stopped abruptly. There are no reports of increased toxicity of propranolol in patients', 'with cancer likewise during combining propranolol with other antineoplastic agents mentioned in', 'Section 1.2.3.', 'Because sunitinib can prolong the PR interval of the electrocardiogram in some patients,', 'theoretically, its coadministration with propranolol, which also prolongs the PR interval, may result in', 'increased risk of conduction disturbances and atrioventricular block. Thus, caution is advised if', 'sunitinib is used concomitantly with propranolol, especially in the elderly and patients with known', 'conduction problems (e.g., marked first-degree atrioventricular [AV] block; second-degree or higher', 'AV block; sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial', 'ischemia or heart failure. Despite the presence of sunitinib for more than 10 years in clinical practice,', 'Page 19 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'no serious cardiac and other type toxicity was reported for coadministration of sunitinib and', 'propranolol.', '1.3 Study Rationale', 'Nowadays, first-line treatment with sunitinib is standard of care in patients with metastatic RCC who', 'are classified into favourable- or intermediate-risk group according to Memorial Sloan-Kettering', 'Cancer Center (MSKCC) criteria. However, disease progression occurs in most cases as cancer cells', 'are primary or secondary resistant to sunitinib. Therefore, new strategies are needed to provide an', 'improved option with maximal curative potential. New therapeutic approaches include combining', 'sunitinib with autologous dendritic cell immunotherapy, AGS-003 (NCT01582672), PD-L1 inhibitor', 'atezolizumab with VEGF inhibitor bevacizumab (NCT02420821), PD-L1 inhibitor avelumab with', 'VEGFR inhibitor axitinib (NCT02684006), VEGFR/fibroblast growth factor receptor (FGFR) inhibitor', 'lenvatinib with PD-1 inhibitor pembrolizumab (NCT02811861) and dual checkpoint inhibition: PD-1', 'inhibitor nivolumab with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor ipilimumab', '(NCT02231749).', 'Other directions in development of improved treatment options in metastatic RCC are focused on', 'drugs available on the market for years that are prescribed primarily for non-malignant diseases.', 'Their antitumor activity was confirmed in preclinical studies and now they are being investigated in', 'clinical trials. These studies include dalteparin, a low molecular weight heparin (LMWH) in', 'combination with sunitinib in first-lline setting (NCT01061411); prednisone, a glucocorticoid, in', 'combination with everolimus in VEGFR pre-treated patients (NCT02479490); hydroxychloroquine,', 'antimalaric drug, in combination with IL-2 (NCT01550367); metformin, an anti-diabetic biguanide, in', 'combination with vandetanib in hereditary leiomyomatosis and renal cell cancer (HLRCC), succinate-', 'dehydrogenase (SDH) mutation-associated RCC (SDH-RCC) or sporadic papillary RCC (NCT02495103);', 'a monotherapy with low dose naltrexone, an opioid antagonist, for metastatic melanoma, castrate', 'resistant prostate cancer or RCC (NCT01650350).', 'Since 1960s, propranolol is used worldwide in different indications, mostly for treatment of', 'cardiovascular diseases. Despite numerous pre-clinical and clinical studies that described its', 'antineoplastic potential, it was not studied extensively as a pure anti-cancer agent in RCC. In the', 'current clinical practice, its anti-tumour activity is limited to benign tumour - IH. Due to favourable', 'toxicity profile and 82-100% overall response rate, oral propranolol is first-line option in treatment of', 'IH, particularly for complicated and ulcerated forms. It has early, intermediate and long-term', 'pharmacological effect on IH. The early effect is a visible change in colour and softening of the lesion', 'that occurs 1-3 days since the therapy initiation. This is related to the \u00df2 inhibition which results in', 'vasoconstriction due to decreased concentration of vasodilators, such as nitric oxide. The', 'intermediate effect involves inhibition of proangiogenic cascade and angiogenesis as a consequence', 'of VEGF and fibroblast growth factor (FGF) downregulation. The long term effect is due to cell', 'apoptosis resulting in regression of haemangiomas [93]. In the recent consensus, a target daily dose', 'of 1-3 mg/kg has been recommended [94]. Based on a randomized controlled trial performed by', 'Hogeling et al., the treatment should last for at least 6 months which can be modified according to', 'the morphological subtypes [95].', 'Page 20 of 60']\n\n###\n\n", "completion": "END"}